CVA Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $170K | Sell |
382
-45
| -11% | -$20K | 0.02% | 317 |
|
|
2025
Q1 | $207K | Buy |
427
+44
| +11% | +$21.3K | 0.03% | 273 |
|
|
2024
Q4 | $154K | Buy |
383
+35
| +10% | +$14.1K | 0.02% | 310 |
|
|
2024
Q3 | $162K | Buy |
348
+9
| +3% | +$4.19K | 0.03% | 296 |
|
|
2024
Q2 | $159K | Buy |
339
+13
| +4% | +$6.09K | 0.03% | 279 |
|
|
2024
Q1 | $136K | Buy |
326
+1
| +0.3% | +$418 | 0.02% | 304 |
|
|
2023
Q4 | $132K | Buy |
+325
| New | +$132K | 0.03% | 296 |
|
|
2023
Q3 | – | Sell |
-300
| Closed | -$106K | – | 931 |
|
|
2023
Q2 | $106K | Buy |
300
+5
| +2% | +$1.76K | 0.02% | 304 |
|
|
2023
Q1 | $92.9K | Sell |
295
-100
| -25% | -$31.5K | 0.02% | 322 |
|
|
2022
Q4 | $114K | Buy |
395
+120
| +44% | +$34.7K | 0.03% | 273 |
|
|
2022
Q3 | $80K | Buy |
275
+40
| +17% | +$11.6K | 0.02% | 273 |
|
|
2022
Q2 | $66K | Hold |
235
| – | – | 0.02% | 310 |
|
|
2022
Q1 | $61K | Buy |
235
+135
| +135% | +$35K | 0.01% | 361 |
|
|
2021
Q4 | $22K | Buy |
+100
| New | +$22K | 0.01% | 513 |
|
|
2021
Q3 | – | Sell |
-91
| Closed | -$18K | – | 876 |
|
|
2021
Q2 | $18K | Sell |
91
-64
| -41% | -$12.7K | 0.01% | 555 |
|
|
2021
Q1 | $33K | Buy |
+155
| New | +$33K | 0.01% | 328 |
|